KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) Cost of Revenue: 2014-2024

Historic Cost of Revenue for Travere Therapeutics (TVTX) over the last 11 years, with Dec 2024 value amounting to $7.7 million.

  • Travere Therapeutics' Cost of Revenue fell 2.52% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.3 million, marking a year-over-year increase of 5.98%. This contributed to the annual value of $7.7 million for FY2024, which is 32.37% down from last year.
  • Travere Therapeutics' Cost of Revenue amounted to $7.7 million in FY2024, which was down 32.37% from $11.4 million recorded in FY2023.
  • Travere Therapeutics' 5-year Cost of Revenue high stood at $11.4 million for FY2023, and its period low was $3.8 million during FY2021.
  • For the 3-year period, Travere Therapeutics' Cost of Revenue averaged around $7.9 million, with its median value being $7.7 million (2024).
  • As far as peak fluctuations go, Travere Therapeutics' Cost of Revenue slumped by 37.68% in 2021, and later soared by 159.05% in 2023.
  • Yearly analysis of 5 years shows Travere Therapeutics' Cost of Revenue stood at $6.1 million in 2020, then plummeted by 37.68% to $3.8 million in 2021, then climbed by 15.77% to $4.4 million in 2022, then skyrocketed by 159.05% to $11.4 million in 2023, then tumbled by 32.37% to $7.7 million in 2024.